164 results
Page 3 of 9
424B5
mpkh5730jnta7
3 Jun 22
Prospectus supplement for primary offering
9:45pm
8-K
EX-99.1
9kxo0n7wcklw60a awmc
6 May 22
Regulation FD Disclosure
2:50pm
8-K
EX-99.1
jpaima3s
28 Apr 22
Regulation FD Disclosure
2:35pm
424B3
s723keuamg5rzraa2o2
25 Apr 22
Prospectus supplement
5:02pm
8-K
EX-10.1
tyb75c196fg13jxqk
7 Apr 22
Entry into a Material Definitive Agreement
4:47pm
424B3
lamf90hb vr
7 Apr 22
Prospectus supplement
4:46pm
8-K
EX-10.1
qxult5
22 Mar 22
Entry into a Material Definitive Agreement
6:05am
S-3
barp2rolokx f3
4 Feb 22
Shelf registration
4:36pm
8-K
EX-99.1
p9kx3
19 Jan 22
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
4:09pm
8-K
EX-99.1
ly8mk81gkm8pn
5 Jan 22
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
2:22pm
8-K/A
EX-99.3
61jat8
22 Dec 21
Audited Financial Statements
12:00am
8-K/A
EX-99.2
3z9p0z8xkdzi
22 Dec 21
Audited Financial Statements
12:00am
8-K/A
EX-99.1
jsloq
22 Dec 21
Audited Financial Statements
12:00am
DEF 14A
n6a2xmuci8vvreqeowo7
28 Oct 21
Definitive proxy
3:07pm
8-K
EX-2.1
y43hodd6z na0i2qn
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm